Skip to content
Screener

Tandem Diabetes Care TNDM Operating Cash Flow

Operating Cash Flow at other companies

Insulet logo
InsuletPODD
$88.4M-55.0%
Medtronic logo
MedtronicMDT
$2.57B+1.8%
Beta Bionics logo
Beta BionicsBBNX
-$14.62M-7.6%
Embecta Corp. logo
Embecta Corp.EMBC
$41.8M-48.5%
AdaptHealth logo
AdaptHealthAHCO
$93.72M-1.9%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$970K-45.5%

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.56B+128%
Enterprise value$2.23B+109%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Deferred revenue(3,782)(2,710)
Operating leases and other current liabilities4,0958,403
Other long-term liabilities(3,280)4,851
Net cash used in operating activities(23,576)(27,774)
Investing Activities
Purchases of short-term investments(260,512)(26,496)
Proceeds from maturities and redemptions of short-term investments69,473146,447
Purchases of property and equipment(10,318)(9,171)

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's operating cash flow?
Tandem Diabetes Care (TNDM) reported operating cash flow of -$34.63M in Q2 2026.
How has Tandem Diabetes Care's operating cash flow changed year-over-year?
Tandem Diabetes Care's operating cash flow decreased by 264.7% year-over-year, from -$9.5M to -$34.63M.
What is the long-term trend for Tandem Diabetes Care's operating cash flow?
Over 3 years (2021 to 2024), Tandem Diabetes Care's operating cash flow has grown at a -39.9% compound annual growth rate (CAGR), from $111.36M to $24.23M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Tandem Diabetes Care's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude